Pro-inflammatory allogeneic DCs promote activation of bystander immune cells and thereby license antigen-specific T-cell responses

References

• Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12:265–77. doi:10.1038/nrc3258. PMID:22437871.
   PubMed Web of Science ®Google Scholar
• Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 2014;15:e257–67. doi:10.1016/S1470-2045(13)70585-0. PMID:24872109.
   PubMed Web of Science ®Google Scholar
• Sabado RL, Bhardwaj N. Directing dendritic cell immunotherapy towards successful cancer treatment. Immunotherapy. 2010;2:37–56. doi:10.2217/imt.09.43. PMID:20473346.
   PubMed Web of Science ®Google Scholar
• Yewdall AW, Drutman SB, Jinwala F, Bahjat KS, Bhardwaj N. CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells. PLoS One. 2010;5:e11144. doi:10.1371/journal.pone.0011144. PMID:20585396.
   PubMed Web of Science ®Google Scholar
• Liu C, Lou Y, Lizee G, Qin H, Liu S, Rabinovich B, Kim GJ, Wang YH, Ye Y, Sikora AG, et al. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest. 2008;118:1165–75. PMID:18259609.
   PubMed Web of Science ®Google Scholar
• Pang IK, Ichinohe T, Iwasaki A. IL-1R signaling in dendritic cells replaces pattern-recognition receptors in promoting CD8(+) T cell responses to influenza A virus. Nat Immunol. 2013;14:246–53. doi:10.1038/ni.2514. PMID:23314004.
   PubMed Web of Science ®Google Scholar
• Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol. 2005;6:769–76. doi:10.1038/ni1223. PMID:15995707.
   PubMed Web of Science ®Google Scholar
• Lovgren T, Sarhan D, Truxova I, Choudhary B, Maas R, Melief J, et al. Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-gamma and multiple toll-like receptor agonists. Cancer Immunol Immunother. 2017;66:1133–44. doi:10.1007/s00262-017-2029-4. PMID:28601925.
   PubMed Web of Science ®Google Scholar
• Wallgren AC, Andersson B, Backer A, Karlsson-Parra A. Direct allorecognition promotes activation of bystander dendritic cells and licenses them for Th1 priming: A functional link between direct and indirect allosensitization. Scand J Immunol. 2005;62:234–42. doi:10.1111/j.1365-3083.2005.01663.x. PMID:16179010.
   PubMed Web of Science ®Google Scholar
• Yu D, Jin C, Leja J, Majdalani N, Nilsson B, Eriksson F, Essand M. Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors. J Virol. 2011;85:13114–23. doi:10.1128/JVI.05759-11. PMID:21957304.
   PubMed Web of Science ®Google Scholar
• Yu D, Jin C, Ramachandran M, Xu J, Nilsson B, Korsgren O, Le Blanc K, Uhrbom L, Forsberg-Nilsson K, Westermark B, et al. Adenovirus serotype 5 vectors with Tat-PTD modified hexon and serotype 35 fiber show greatly enhanced transduction capacity of primary cell cultures. PLoS One. 2013;8:e54952. doi:10.1371/journal.pone.0054952. PMID:23372800.
   PubMed Web of Science ®Google Scholar
• Sester DP, Thygesen SJ, Sagulenko V, Vajjhala PR, Cridland JA, Vitak N, Chen KW, Osborne GW, Schroder K, Stacey KJ, et al. A novel flow cytometric method to assess inflammasome formation. J Immunol. 2015;194:455–62. doi:10.4049/jimmunol.1401110. PMID:25404358.
   PubMed Web of Science ®Google Scholar
• Hillerdal V, Boura VF, Bjorkelund H, Andersson K, Essand M. Avidity characterization of genetically engineered T-cells with novel and established approaches. BMC Immunol. 2016;17:23. doi:10.1186/s12865-016-0162-z. PMID:27411667.
   PubMed Web of Science ®Google Scholar
• Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med. 2000;192:1213–22. doi:10.1084/jem.192.9.1213. PMID:11067871.
   PubMed Web of Science ®Google Scholar
• Tacken PJ, Figdor CG. Targeted antigen delivery and activation of dendritic cells in vivo: steps towards cost effective vaccines. Semin Immunol. 2011;23:12–20. doi:10.1016/j.smim.2011.01.001. PMID:21269839.
   PubMed Web of Science ®Google Scholar
• Kerkar SP, Leonardi AJ, van Panhuys N, Zhang L, Yu Z, Crompton JG, Pan JH, Palmer DC, Morgan RA, Rosenberg SA, et al. Collapse of the tumor stroma is triggered by IL-12 induction of Fas. Mol Ther. 2013;21:1369–77. doi:10.1038/mt.2013.58. PMID:23568260.
   PubMed Web of Science ®Google Scholar
• Tugues S, Burkhard SH, Ohs I, Vrohlings M, Nussbaum K, Vom Berg J, Kulig P, Becher B. New insights into IL-12-mediated tumor suppression. Cell Death Differ. 2015;22:237–46. doi:10.1038/cdd.2014.134. PMID:25190142.
   PubMed Web of Science ®Google Scholar
• Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwari S, Kleinman HK, Reaman GH, Tosato G. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med. 1995;182:155–62. doi:10.1084/jem.182.1.155. PMID:7540647.
   PubMed Web of Science ®Google Scholar
• Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, Luster AD. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol. 2002;168:3195–204. doi:10.4049/jimmunol.168.7.3195. PMID:11907072.
   PubMed Web of Science ®Google Scholar
• Barlan AU, Griffin TM, McGuire KA, Wiethoff CM. Adenovirus membrane penetration activates the NLRP3 inflammasome. J Virol. 2011;85:146–55. doi:10.1128/JVI.01265-10. PMID:20980503.
   PubMed Web of Science ®Google Scholar
• Bouwer AL, Saunderson SC, Caldwell FJ, Damani TT, Pelham SJ, Dunn AC, Jack RW, Stoitzner P, McLellan AD. NK cells are required for dendritic cell-based immunotherapy at the time of tumor challenge. J Immunol. 2014;192:2514–21. doi:10.4049/jimmunol.1202797. PMID:24477907.
   PubMed Web of Science ®Google Scholar
• Anguille S, Van Acker HH, Van den Bergh J, Willemen Y, Goossens H, Van Tendeloo VF, Smits EL, Berneman ZN, Lion E. Interleukin-15 Dendritic Cells Harness NK Cell Cytotoxic Effector Function in a Contact- and IL-15-Dependent Manner. PLoS One. 2015;10:e0123340. doi:10.1371/journal.pone.0123340. PMID:25951230.
   PubMed Web of Science ®Google Scholar
• Vandenberk L, Belmans J, Van Woensel M, Riva M, Van Gool SW. Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines. Front Immunol 2015;6:663. PMID:26834740.
   PubMed Web of Science ®Google Scholar
• Pascutti MF, Rodriguez AM, Falivene J, Giavedoni L, Drexler I, Gherardi MM. Interplay between modified vaccinia virus Ankara and dendritic cells: Phenotypic and functional maturation of bystander dendritic cells. J Virol. 2011;85:5532–45. doi:10.1128/JVI.02267-10. PMID:21411535.
   PubMed Web of Science ®Google Scholar
• Laurell A, Lönnemark M, Brekkan E, Magnusson A, Tolf A, Wallgren AC, Andersson B, Adamson L, Kiessling R, Karlsson-Parra A, et al. Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma. J Immunother Cancer. 2017;5:52. doi:10.1186/s40425-017-0255-0. PMID:28642820.
   PubMed Web of Science ®Google Scholar